#USA #Boston #Field Medical #PFA Technology #FieldForce System

Introduction

At the recent 31st Annual International AF Symposium held in Boston from February 5 to 7, 2026, Field Medical, Inc. made a significant impact by presenting late-breaking clinical trial data from its inaugural human study, Field PULSE. This groundbreaking research focuses on the company’s pulsed field ablation (PFA) technology intended for addressing complex cardiac arrhythmias.

Presentation of Findings

Field Medical introduced a novel high-voltage pulsed field waveform applied via their FieldForce™ ablation system. This innovative system, which utilizes a contact-detecting catheter, enables instantaneous ablation through targeted energy delivery, thereby minimizing the need for prolonged contact between the catheter and the tissue.

Key Insights from the Study

Dr. Vivek Y. Reddy, the lead investigator for the Field PULSE trial and an electrophysiologist based at Mount Sinai in New York, highlighted the advantages of this cutting-edge approach:

• - Instantaneous Energy Delivery: Lesions were created in under 200 milliseconds, allowing for rapid point-by-point ablation.
• - Procedure Efficiency: The average time for bilateral pulmonary vein isolation (PVI) was reduced to 12.5 minutes, with some cases completed in as little as 7.7 minutes.
• - Durability Results: PVI durability showcased improvement, revealing a 94.2% success rate per vein and an 84.6% success rate per patient.

Safety Outcomes

Crucially, the trial reported no severe adverse events connected to the device. Notably, there were no instances of acute kidney injury, phrenic nerve paralysis, or clinically significant hemolysis. Among fourteen patients evaluated via brain MRI, zero silent cerebral lesions were detected, underscoring the safety profile of the PFA approach.

Expanding the Evidence Base

These findings enrich Field Medical's clinical evidence concerning high-voltage focal ablation methods, extending their application from previously studied ventricular arrhythmias to therapies for atrial fibrillation (AF). When combined with earlier findings related to ventricular tachycardia, the results support the potential for a versatile ablation platform applicable to all heart chambers. This development illustrates the feasibility of focal PFA in both atrial and ventricular substrates, while maintaining procedural efficiency.

Testimonials from the Field

In his remarks, Dr. Steven Mickelsen, Field Medical's founder and CTO, shared, "The results from Field PULSE reinforce our commitment to deliberately designing focal PFA to directly tackle the inherent limitations of existing methods while validating our applications with real data. With fast administration of each ablation point, we reduce reliance on prolonged catheter stability and limit the effects of cardiac motion."

Further Discussions at the Symposium

During the symposium, Field Medical was showcased during the Late Breaking Clinical Trials session, where their compelling data was presented. On February 6, the company participated in a scientific session on PFA biophysics featuring a presentation by Dr. Kenneth Ellenbogen titled, "Maximizing Lesion Depth Using High Voltage PFA Waveform." Moreover, on February 7, Dr. Reddy detailed the specifics of AF ablation using the high-voltage PFA catheter in an engaging case presentation.

About the FieldForce™ Ablation System

The FieldForce™ system represents a state-of-the-art contact-based focal ablation technology that harnesses patented FieldBending™ technology. Designed for both atrial and ventricular ablation, it propels Field Medical's vision of a universal ablation platform intended for extensive cardiac treatments.

Conclusion

Field Medical, established in 2022, remains at the forefront of the medical technology sector dedicated to advancing solutions for complex cardiac arrhythmias. The FieldForce system, combined with recent clinical data, illustrates a promising avenue for enhancing patient outcomes in electrical cardiac therapies. For more details on this innovative technology and its applications, visit Field Medical's official website. Follow their updates on LinkedIn, X, and YouTube for ongoing developments in this pioneering research area.